In vivo CAR T-cell therapy: determinants of response and durability.

Authors

Mohamed Abou-El-Enein

Published in

Blood cancer discovery. Sep 23, 2026. Epub Sep 23, 2026.

Abstract

In vivo chimeric antigen receptor (CAR) T-cell therapy generates engineered lymphocytes inside the patient, bypassing leukapheresis, ex vivo manufacturing and, in many programs, lymphodepletion. Studies in relapsed or refractory multiple myeloma report deep responses with measurable residual disease negativity after B-cell maturation antigen-directed treatment. Because the administered product is a delivery system, cells are shaped by the host environment, which may complicate interpretation of efficacy and safety. This Review summarizes clinical data and defines determinants of response that could be optimized for durable translation. It focuses on multiple myeloma, where clinical experience is most mature, while drawing on autoimmune applications.

PMID:
42777095
Bibliographic data and abstract were imported from PubMed on 24 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.